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Abstract. – OBJECTIVE: The aim of the study 
was to evaluate the relationship between bacterial 
vaginosis (BV) and relapse of cervical intraepithe-
lial neoplasia grade 2 or more (CIN2+) after Loop 
electrosurgical excision procedure (LEEP).
PATIENTS AND METHODS: One hundred four 
patients who underwent LEEP for CIN2+ were fol-
lowed up every six months for three years. Fifty-three 
were negative for BV and fifty-one were positive. 
Each clinical control included Pap test, colposcopy, 
Amsel criteria test, HPV-DNA, and HPV-mRNA test. 
RESULTS: Patients’ age, presence of BV, positiv-
ity to HPV-DNA and HPV-mRNA tests were analyzed. 
The average age of patients was 42.5 ± 8.92 years 
(median: 42.5; range from 27 to 58 years). The mini-
mum follow-up was 6 months and maximum 36 
months (average: 22.8 ± 4.53; median: 24). The 10% 
of the patients with HPV-mRNA test negative had re-
lapsed, compared to 45% of patients with HPV-mR-
NA test positive. Among the 53 patients without BV 
the 20% had relapsed compared with 23% of 51 pa-
tients with diagnosis of BV. 
CONCLUSIONS: There is no evidence for higher 
percentage of relapse in patients with BV, submit-
ted to excisional procedure for CIN2+ associated 
to HPV-m-RNA test positivity. There is only a cor-
relation among BV and relapse of CIN2+ lesions af-
ter LEEP. 
Key Words
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Introduction
Bacterial vaginosis (BV) is a common vaginal 
disorder during reproductive’s age women, par-
ticularly in those with age between 25-30 years 
old. It is not an inflammatory process, but rather 
to an alteration of the normal quantitative and 
polymicrobial vaginal ecosystem. BV is characte-
rized by a reduction of vaginal lactobacilli and 
an overgrowth of other (facultative) anaerobic 
bacteria1, such as Gardnerella vaginalis, present 
in 95% of cases of BV, Mobiluncus, Mycoplasma, 
Bacteroides, Prevotella, Peptostreptococcus, Fu-
sobacterium, Porphyromonas, and Senathia2,3. 
BV can be diagnosed by Amsel criteria, mo-
dified Amsel criteria, Nugent’s scoring system or 
Papanicolaou-stained vaginal smears4. BV is cha-
racterized by a gray/white discharge, malodorous 
“fishy” discharge upon adding 10% potassium hy-
droxide, high vaginal pH (>4.5) and the presence 
of clue cells5. Several papers suggested that BV 
may be involved in cervical carcinogenesis6 and 
can be associated to high susceptibility to Human 
Papilloma Virus (HPV) acquisition and a lower 
immunocompetence for clearance HPV infection 
because BV can destroy innate vaginal defenses7.
In literature, the association between BV and 
the onset of cervical intraepithelial neoplasia (CIN) 
has been deeply investigated, while no researches 
have been performed on the role of BV in relapse 
of cervical intraepithelial neoplasia grade 2 or 
more (CIN2+) after Loop Electrosurgical Excision 
Procedure (LEEP), as far as we know. The aim of 
the study was to evaluate the relationship between 
BV and relapse of CIN2+ after LEEP. 
Patients and Methods
 
From January 2010 to September 2015, 104 out 
of 9830 patients have been selected among those 
who attended to Department of Medical and Surgi-
cal Science and Translational Medicine, Sant’An-
drea Hospital, School of Medicine and Psychology, 
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Sapienza University of Rome. Fifty-three out of 
104 patients resulted BV negative and 51 BV po-
sitive. All the patients were positive to HPV-DNA 
test and they underwent to a LEEP for CIN2+. 
The study was reviewed and approved by the 
Institutional Review Board (Prot. CE 1591/13). 
All the women who had been previously treated 
by LEEP and all study participants were provided 
informed written consent. The study was con-
ducted in accordance to the Helsinki Declaration. 
Exclusion criteria were the presence of risk factors 
for preneoplastic cervix injuries such as smoke, 
HIV positivity, menopause, use of progestogens, 
immunosuppression, and pregnancy. 
The Loop Electrosurgical Excision Procedure 
(LEEP) was performed by Ellmann Surgitron 
120  IEC, Dual Radio Frequency equipment, with 
diathermic loops of different measures: small, 10 
x 10 mm; middle-size, 15 x 12 mm; large, 20 x 
15 mm; basing on the localization of the lesions 
and on the dimension of the cervix. 
The sample was stained in 10% formalin and 
analyzed for the histological diagnosis by skilled 
pathologists. Every sample was doubled checked 
by two different pathologists who agree with the 
diagnosis.
All patients performed Pap test. The cyto-
logical findings were formulated according to 
Bethesda System (2001). Women with anomalous 
cytological results: Atypical squamous cells of 
undetermined significance (ASC-US); Atypical 
squamous cells – cannot exclude HSIL (ASC-H) 
Low grade squamous intraepithelial lesion 
(LSIL); High grade squamous intraepithelial lesion 
(HSIL); Atypical Glandular Cells not otherwise 
specified (AGC-NOS) Atypical Glandular Cells, 
suspicious for AIS or cancer (AGC-neoplastic) 
underwent to a colposcopy performed by a Colpo-
scope Zeiss T 50 (Carl Zeiss, Inc., Jena, Germany). 
The colposcopy was considered satisfactory if 
the squamous-columnar junction (SCJ) has been 
entirely identified. The colposcopy findings were 
reported according to the International Classifi-
cation Colposcopic IFCPC 2012. All colposcopic 
direct biopsies were performed in areas that showed 
a higher degree of atypia. All the patients were 
revalued every 6 months for 3 years; at the end of 
this period, the results of Pap test, HPV- DNA test 
and HPV-mRNA test were analyzed. The samples 
for both molecular tests were obtained from the ec-
tocervix and the endocervical canal. The DNA ge-
notyping was performed with the LiPA (Innogene-
tics, Gent, Belgium, EU) using biotinylated SPF10 
PCR primers for the amplification of a 65-bp region 
of the L1 gene of a broad spectrum of HPV types 
(AmpliTaq Gold DNA polymerase; Applied Biosy-
stems, Foster City, CA, USA). LiPA is capable of 
detecting 26 HPV types: high-risk HPV genotypes 
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 and 
70; low-risk HPV genotypes 6, 11, 34, 40, 42, 43, 44, 
53, 54 and 74. The assay was performed according 
to the manufacture’s protocol. For the detection 
of E6/E7 mRNA of HPV types 16, 18, 31, 33 and 
45 the PreTect HPV-Proofer Kit (referred to as the 
mRNA test) (NorChip, Klokkaarstua, Norway) was 
used, according to the manufacturer’s instructions. 
The mRNA was extracted using Rneasy Mini Kit 
(QIAGEN, Gaithersburg, MD, USA).
The diagnosis of BV was based on the pre-
sence of at least three of four Amsel’s criteria: 1) 
thin, gray/white discharge; 2) malodorous “fishy” 
discharge upon adding 10 % potassium hydroxi-
de; 3) high vaginal pH (>4.5), and 4) identifica-
tion of vaginal epithelial cells heavily coated with 
bacteria, “clue cells”.
Statistical Analysis 
Patient age, number of follow-up months, num-
ber of follow-up check-ups with a pathologic finding 
(presence of BV, HPV-m RNA positivity, relapse of 
the lesion) per patient, as mean ± standard deviation 
and median with range were described. We used pa-
tient stratified, time-dependent Cox regression mod-
els to evaluate the effect of the age of the patient, the 
presence of BV and HPV-m RNA positivity during 
each follow-up on the occurrence of relapse at the 
check-ups. Time-dependent Cox regression models 
allow to study the effect of time-varying risk factors 
on the incidence of a recurrent event during multiple 
observations of one patient, while the standard Cox 
model evaluates only the risk that such event can 
happen just once per patient.
We first analyzed the univariate relationship 
between the observed variables and the occurrence 
of relapse of the lesion; in this analysis, age was 
grouped into four categories (27-35, 36-42, 43-49, 
50-58 years) and the younger age group was used 
as reference. Then, we built a multivariable model 
which evaluate also how the interaction between 
presence of BV and HPV-m RNA positivity influ-
ences such risk. Finally, we evaluated the effect 
of this interaction separately with a multivariable 
model for each age group, in order to evaluate the 
influence of age on such relationship. We report 
incident rate ratios (IRR), which represent the 
multiplicative effect on the risk of a relapse at 
each check-up, together with the 95% Confidence 
Intervals (95% CI), the statistic of the relationship 
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and the p-value. When describing multivariable 
models, we reported the adjusted IRR (aIRR). 
Data analysis and plotting were performed using 
the R statistical language v. 3.2.0.
Results
The average age of patients was 42.5 ± 8.92 
years (median: 42.5, range from 27 to 58 years). The 
minimum follow-up was 6 months and the maxi-
mum 36 months (average: 22.8 ± 4.53, median: 24). 
In Table I are shown the data relating to the 
CIN lesion’s relapse, the presence of BV and 
positive of HPV-mRNA test. In Table II are 
described the variables: patients’ age, presence 
of BV, positivity to HPV-mRNA test. Figure 1 
shows financial results of the Cox models for each 
of the 2 table variables.
We divided the age of the patients into quar-
tiles (27-35, 36-42, 43-49, 50-58 years) (Figure 
1): in the first quartile, 23% of patients relapsed, 
in the second one 19% relapsed, in the third one 
Table I. Number of women who have had at least one relapse, a diagnosis of BV, a positive HPV mRNA test to the controls, 
mean ± SD number and range of these women’s events.
  No. of patients Average ± DS Max – min
  women’s events women’s events  
Relapse 23 (22.1%) 0.683 ± 1.4 0 – 5
Presence of BV 51 (49.0%) 1.9 ± 1.99 0 – 5
HPV mRNA pos. 36 (34.6%) 0.865 ± 1.34 0 – 5
Table II. Statistical relationship between the variables and the risk of relapse. The table shows the results of three separate 
models, independent of each other.
Age group  aHR IC 95% Statistics p-value  
36-42 years 0.906 [0.238, 3.44] -0.145 0.884 ns
43-49 years 0.957 [0.298, 3.08] -0.0732 0.942 ns
50-58 years 1.36 [0.41, 4.49] 0.5 0.617 ns
Presence of BV 1.74 [0.73, 4.15] 1.25 0.211 ns
HPV mRNA pos. 10.1 [4.83, 21] 6.17 <0.001 ***
Figure 1. Relationship between risk of relapse and the age group, presence of BV and positive to mRNA test. 
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23% relapsed, in the last one 18% relapsed. Fig-
ure 1 shows the relapse based on the presence of 
BV. Among the 53 patients without BV, the 20% 
had relapsed compared with 23% of 51 patients 
with diagnosis of BV.
Finally, Figure 1 shows the relapse based on 
positivity of mRNA test. The 10% of the patients 
with HPV-mRNA test negative had relapsed com-
pared to 45% of patients with HPV-mRNA test 
positive. Table III shows the independent contri-
bution of the presence of BV and HPV-mRNA 
on the risk of relapse and the interaction between 
these two factors.
In Table IV is shown as the relationship between 
BV, HPV-mRNA, relapse and age, changes accord-
ing to age group. In Figure 2, the graphic rendering 
of mentioned relationship is summarized.
Discussion
Human papillomavirus (HPV) is one of the 
most common sexually transmitted infection8. 
The natural history of HPV demonstrates that 
the virus can disappear naturally9 and the lesions 
may undergo a spontaneous regression10. Persistent 
high-risk HPV infection is associated with neo-
plastic lesions of the uterine cervix; therefore, ma-
ny studies suggest that HPV is a necessary, but not 
sufficient, condition for cervical carcinogenesis8.
Risk factors for HPV disease can be young 
age at first intercourse, multiple sexual partners, 
cigarette smoking, race, high parity, oral contra-
ceptive use and low socio-economic status11,12. 
Since 1970s several trials report a possible asso-
ciation between vaginal microenvironment, BV, and 
cervical carcinogenesis that it is actually debated.
Hudson et al13 found that in phase of squa-
mous metaplasia, basic pH typical of BV could 
make the transformation zone more vulnerable to 
agents promoting dysplasia such as HPV. Accord-
ing to the study of Bauer et al14 lactobacilli could 
have a protective effect through oxygen species 
interaction: producing lactobacilli could be a nat-
ural anti-cancer in vaginal microbioma of healthy 
women. In the presence of bacterial vaginosis, the 
depletion of lactobacilli and a relative absence of 
hydrogen peroxide (H2O2) alters this microbicidal 
vaginal environment reducing anti-tumor effect. 
Furthermore, biochemical changes in vaginal se-
cretions of women with BV include the presence 
of nitrosamine produced by anaerobic bacteria: 
harmful substance, capable of forming DNA ad-
ducts and consequently mutagenic events and 
Table III. Model with independent effect and interations between the presence of BV, positive mRNA test and risk of relapse.
Age group  aHR IC 95% Statistics p-value  
HPV mRNA pos. 18.5 [6.17, 55.2] 5.22 <0.001 ***
Presence of BV 2.9 [0.767, 11] 1.57 0.116 ns
BV X mRNA pos. 0.369 [0.0886, 1.54] -1.37 0.171 ns
Table IV. Variable model that influence relapse, divided by age groups. 
  aHR IC 95% Statistics p-value  
27-35 years 
   Presence of BV 32.2 [5.75, 181] 3.95 <0.001 ***
   HPV mRNA pos. 1.13 [0.0634, 20.1] 0.0821 0.935 ns
   BV X mRNA pos. 0.748 [0.0546, 10.2] -0.218 0.828 ns
36-42 years
   Presence of BV 4.16e+09 [1.61e+09, 1.07e+10] 45.9 <0.001 ***
   HPV mRNA pos. 3.9e+08 [4.51e+07, 3.37e+09] 18 <0.001 ***
   BV X mRNA pos. 7.9e-10 [1.5e-10, 4.16e-09] -24.8 <0.001 ***
43-49 years
   Presence of BV 30 [4.46, 202] 3.5 <0.001 ***
   HPV mRNA pos. 9.48 [0.935, 96] 1.9 0.057 .
   BV X mRNA pos. 0.277 [0.0283, 2.71] -1.1 0.270 ns
50-58 years
   Presence of BV 6.06e-08 [5.63e-09, 6.51e-07] -13.7 <0.001 ***
   HPV mRNA pos. 1 [0.141, 7.16] 0.00347 0.997 ns
   BV X mRNA pos. 1.03e+08 [5.97e+06, 1.77e+09] 12.7 <0.001 ***
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metabolic by-products, like propionate and butyr-
ate, capable of damaging epithelial cells15,16 and 
interfere with the TLR-mediated inflammatory 
response17,18. Briselden et al19 reported a positivity 
for mucin-degrading enzymes, in particularly 
sialidases, in 84% of BV-positive women. These 
enzymes destroy the gel layer coating the cervi-
cal epithelium, promoting susceptibility to cervi-
cal HPV infection19,20.
Gardnerella vaginalis, anaerobic bacteria fre-
quently involved in BV, through sialidases, degrades 
host defence molecules such as Immunoglobulin-A 
(IgA) against G vaginalis hemolysin21. This enzyme 
removes sialic acid from secretory IgA and conse-
quently reduces local immune response22. 
Furthermore, studies investigating the BV role 
in vaginal immunity disorders and, in the de-
creased clearance of high-risk papilloma virus in-
fection, it assumed a favorable factor of vaginosis 
in the persistence of HPV infection23-24. 
BV and HPV infection occur in sexually-active 
women, but their temporal relationship is still con-
troversial. Mao et al26 reported that HPV infection 
generally occurs first or at the same time as BV, 
while Guo et al24 showed that BV is previous to 
HPV infection and that a vaginal microenviron-
ment is a protective factor. 
Indeed the composition of vaginal flora and 
commensal vaginal Lactobacillus spp play an 
important role against urogenital diseases, such 
as bacterial vaginosis, sexually transmitted in-
fections or urinary tract infections. Ravel et al27 
reported in their study five major community 
state types present in vaginal microbiota: the 
vaginal microbioma characterized by low num-
bers of Lactobacillus and higher diversity of 
anaerobic bacteria (typical of BV) has been asso-
ciated with slow regression of HPV28. According 
to Mitra et al29, this vaginal microenvironment 
can be associated with higher incidence of HPV 
infection and CIN; through the use of Next Gen-
eration Sequencing (NGS) they identified 5 major 
community – state types (CST): CST I, II, III, 
V characterized by Lactobacillus crispatus, L. 
gasseri, L. iners and L. jensenii respectively and 
CST IV characterized by low numbers of Lacto-
bacillus spp. and higher of presence of anaerobic 
bacteria. The results of their study showed that 
CST IV microbiome is associated with greater 
risk of progression of HPV infection and of 
CIN severity. Indeed the differences in the com-
position of the vaginal microenvironment may 
be correlated with increasing severity of HPV 
lesion. In the presence of LSIL there is a signifi-
cant concentration of Lactobacilli (lactobacillus: 
jensenii p-value < 0.01, coleohominis p-value < 
0.05) while in the presence of HSIL, high levels 
of enterobacteriaceae were found as Peptostrep-
Figure 2. Relationship between relapse and age group, presence of BV, positive HPV mRNA test. 
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tococcus anaerobium (p-value applies < 0.05) 
and Anaerococcus tetradius p-value <0.05, Fu-
sobacteria to Sneathia sanguinegens p-value < 
0.01. However, the relationship between BV and 
cervical intraepithelial neoplasia is still debated. 
A clinical trial30 proved that cervical cytolog-
ical abnormalities are more frequently in women 
with a disrupted vaginal flora and suggested 
a possible link between BV and the develop-
ment of cervical cancer. Another retrospective 
cohort-study32 described in follow-up smear of 
women with BV higher rate of LSIL and HSIL 
(OR 1.89, 95% CI 1.41-2.52). 
Lehtovirta et al31 found an increasing risk of 
CIN in patients with BV in an univariate anal-
ysis (Hazard ratio 1.85, 95% CI 1.04-3.28) and 
in 2012, Gillet et al33 evaluated the association 
between BV and CIN in a meta-analytic survey. 
Even if there was substantial heterogeneity 
among the various studies, (X2 = 164.7) a positive 
correlation between BV and CIN (odd ratio 1.51; 
95% CI, 1.24-1.83) has been found, in patients 
showing positive Pap test or testing positive for 
vaginal smear and for HPV-DNA test. However, 
this correlation could be affected by the presence 
of other risk factors, therefore we enrolled in our 
study patients, without others risk factors34 for the 
CIN. In literature, the relationship between BV 
and onset of CIN has been widely analyzed com-
pared to the relationship between BV and relapse 
of CIN subsequently LEEP surgery. Therefore we 
focused on the recurrence in patients previously 
surgically treated for CIN2+ after LEEP. Our data 
showed that the BV has a role in the risk of re-
lapse (1.74 aHR), but the risk assessment has been 
made difficult by the presence of not considered 
confounding and interaction factors and the small 
number of patients (p-value = 0.211 ns). We divid-
ed the patients into quartiles to evaluate the role of 
age on the risk of relapse but the results obtained 
were not statistically significant (age 27-35 p-value 
=, age 36-42 p-value = 0.884, age 50-58 p-value = 
0.617). We also decided to analyze the role use of 
viral biomarkers as HPV DNA test or HPV mRNA 
test in the presence of cervical HPV infection be-
cause they can improve a correct clinical approach. 
A positive HPV-DNA test for 12-24 months 
represents a risk index of the onset of CIN. Our 
previous study35 analyzed the relationship BV and 
CIN and whether this correlation was increased 
in the presence of HPV-DNA positive test. In the 
current study, has been employed not only the 
HPV-DNA test, but also the HPV-mRNA test that is 
based on the lesser expression of viral oncoproteins 
in transient infections than transformative. This 
molecular test was used to evaluate the follow-up 
and relapse of CIN2+ after LEEP. We observed no 
important differences about the presence of HPV 
in the two groups as the patients were tested pos-
itive for HPV DNA test. Furthermore, the results 
of our study showed the relationship between the 
positivity of HPV- mRNA test and the occurrence 
of recurrences: it was greater than ten times of 
controls with mRNA negative test. In Table III and 
Figure 2a, we analyzed the interaction between 
VB and the positivity of HPV- mRNA test. The 
patients were divided into four groups (VB / mR-
NA-; VB+ / HPV-mRNA-; VB- / HPV-mRNA+; 
VB+ / HPV-mRNA+). In the first and second group 
(HPV- mRNA negative) of Figure 2, the presence 
of the VB increased the risk of recurrence, but not 
significantly (p-value = 0.116 ns), while in the third 
and fourth group (HPV mRNA positive) the recur-
rence appeared in a higher rate of cases. Analyzing 
the data of the fourth group the simultaneous pres-
ence of VB and HPV-mRNA positive test increased 
the risk of recurrence, but less than the sum of the 
effects of the two variables (p-value: 0.171 ns). 
Referring to Figure 2b and Table IV, the positivity 
to BV in presence of HPV-mRNA did not modify 
the risk of relapse in age groups between 27-35 
years (p-value = 0.935 ns) and between 50-58 years 
(p-value = 0.997), and conversely the positivity to 
BV in presence of HPV- mRNA modified the risk 
of recurrence of CIN in age groups between 36-42 
years (p-value < 0.001) and 43-49 years (p-value < 
0.059). Our results show that the presence of VB 
and of mRNA decreases the risk of recurrence 
in first, second and third age group, especially in 
second age group (36-42 years). Instead, HPV-mR-
NA positivity seemed to have a protective role on 
relapse in older patients, but the interaction between 
the BV and HPV-mRNA in this group seemed to 
promote the relapse.
The division into age groups decreases the 
size of the sample becoming a limiting factor for 
the clinical results.
Conclusions
No significant statistical differences can be 
demonstrated comparing the results between the 
positive BV group and the negative BV group in 
terms of cervical intraepithelial lesions’ relapse. 
Further studies would be needed to define the 
role of BV and its correlation with CIN occur-
rence in a larger cohort of patients.
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